{"id":"tcg","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL448644","moleculeType":"Small molecule","molecularWeight":"3740.38"},"_dailymed":{"setId":"9229f871-bc61-4ddc-8122-d126d40e36ac","title":"SKYTROFA (LONAPEGSOMATROPIN-TCGD) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASCENDIS PHARMA ENDOCRINOLOGY, INC.]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TCG is a medication that specifically targets and inhibits the activity of certain enzymes, which are involved in the breakdown of certain fatty acids. This mechanism of action leads to a decrease in the production of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol in the liver, resulting in a reduction of triglyceride levels in the blood.","oneSentence":"TCG works by inhibiting the activity of certain enzymes in the body.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:34.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertriglyceridemia"},{"name":"Mixed dyslipidemia"}]},"trialDetails":[{"nctId":"NCT02143518","phase":"PHASE1","title":"Safety and Immunogenicity Study of Na-GST-1 With or Without CpG","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2014-10","conditions":"Hookworm Infection, Hookworm Disease","enrollment":24},{"nctId":"NCT04528173","phase":"PHASE4","title":"Opioid-Free Anesthetic for Tonsillectomy","status":"TERMINATED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-07-22","conditions":"Anesthesia, Opioid Use, Tonsillitis","enrollment":35},{"nctId":"NCT05821062","phase":"","title":"Antiplatelet Therapies in Patients With Depression and Coronary Disease","status":"UNKNOWN","sponsor":"Centro Cardiologico Monzino","startDate":"2022-04-14","conditions":"Coronary Artery Disease, Depression","enrollment":400},{"nctId":"NCT04830319","phase":"NA","title":"Pilates Method in People With HAM/TSP","status":"COMPLETED","sponsor":"Pedreira, Érika, M.D.","startDate":"2018-02-20","conditions":"HAM/TSP, HTLV-1 Secondary Myelopathy, Balance","enrollment":22},{"nctId":"NCT00052468","phase":"PHASE3","title":"Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"AGO Study Group","startDate":"2002-08","conditions":"Fallopian Tube Cancer, Ovarian Cancer","enrollment":1742}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Paclitaxel/Carboplatin/Gemcitabine"],"phase":"marketed","status":"active","brandName":"TCG","genericName":"TCG","companyName":"AGO Study Group","companyId":"ago-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TCG works by inhibiting the activity of certain enzymes in the body. Used for Hypertriglyceridemia, Mixed dyslipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}